MedPageToday -- The investigational anti-inflammatory naproxcinod may eliminate the blood pressure elevations common with nonsteroidal anti-inflammatory drugs used in osteoarthritis, a pooled safety analysis suggested. Naproxcinod -- which breaks down into the NSAID naproxen and a nitric oxide donor -- was no different than placebo in its effect on systolic blood pressure in osteoarthritis patients (mean change -0.4 mm Hg from baseline versus placebo, 95% CI -1.6 to 0.8), William B. White, MD, of the University of Connecticut in Farmington, and colleagues found.
